# Defibrotide for the Treatment of Severe COVID-19

> **NCT04652115** · PHASE2 · RECRUITING · sponsor: **Brigham and Women's Hospital** · enrollment: 42 (estimated)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Defibrotide

## Key facts

- **NCT ID:** NCT04652115
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-01
- **Primary completion:** 2024-09-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2024-05-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04652115

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04652115, "Defibrotide for the Treatment of Severe COVID-19". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04652115. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*